Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
1987: Company is founded by cousins Steven Sablotsky and Mitchell Goldberg.
Noven made quick strides in developing an estrogen patch and as early as 1989 the company was able to sign a worldwide licensing agreement, with the exception of Japan, for its transdermal estrogen delivery system.
In 1991 revenue dipped below $200,000 while losses topped $3 million.
1994: First product gains FDA approval.
In January 1995 another estrogen patch, produced by Berlex Laboratories, received FDA approval and it appeared that it would become available in the United States and Canada in the next three or four months.
By the spring of 1997 the stock was again trading at the $8 level, due to lower levels of reorders as the company worked through its stockpile of estrogen patches.
South Florida Top Workplaces: Here are the 2021 winners
UPDATED: Celebrate Earth Day/Arbor Day 2021 with free trees, craft projects Apr 15, 2021
Rate how well Noven lives up to its initial vision.
Do you work at Noven?
Does Noven communicate its history to new hires?
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Avanir Pharmaceuticals | 1988 | $115.0M | 200 | - |
| FUJIFILM Irvine Scientific | 1970 | $300.0M | 361 | - |
| Prometheon Pharma | 2011 | $160,000 | 3 | - |
| Oyster Point Pharma | 2015 | $2.2M | 86 | - |
| Antares Pharma | 1979 | $184.0M | 165 | - |
| Alpharma | 1975 | $350.0M | 2,000 | - |
| Depomed | 1995 | $342.7M | 494 | - |
| KV Pharmaceutical | 1942 | $91.0M | 7,500 | - |
| Emisphere Technologies | 1986 | $1.2M | 76 | - |
| Pharmacia | 1901 | $130.0M | 350 | - |
Zippia gives an in-depth look into the details of Noven, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Noven. The employee data is based on information from people who have self-reported their past or current employments at Noven. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Noven. The data presented on this page does not represent the view of Noven and its employees or that of Zippia.
Noven may also be known as or be related to Noven, Noven Pharmaceuticals, Noven Pharmaceuticals Inc and Noven Pharmaceuticals, Inc.